title: Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.
abstract: The introduction of liver transplant listing criteria for hepatocellular cancer (HCC) has significantly improved oncological outcomes and survival. But despite this HCC recurrence is still problematic. There is emerging evidence that the choice of immunosuppression (IS) after transplant for HCC can influence oncological survival and HCC recurrence. The following is a short summary of what has been published on HCC recurrence with the different classes of immunosuppressive agents in present use, concluding with the possible rationalization of the use of these immunosuppressive agents in the post-transplant patient at high risk of recurrence.
authors.affiliation: Institute of Liver Studies, King's Healthcare Partners at Denmark Hill, King's College Hospital NHSFT, London, SE5 9RS, UK.
authors.forename: Shirin Elizabeth
authors.initials: SE
authors.lastname: Khorsandi
authors.affiliation: Institute of Liver Studies, King's Healthcare Partners at Denmark Hill, King's College Hospital NHSFT, London, SE5 9RS, UK.
authors.forename: Nigel
authors.initials: N
authors.lastname: Heaton
keywords: Liver transplant; chemotherapy; hepatocellular cancer (HCC); immunosuppression (IS)